Medical imaging software developer MIM Software has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its SurePlan MRT molecular radiotherapy software.
The company was given clearance for new artificial intelligence (AI)-based segmentation models that simplify the contouring process for dosimetry. The software's AI segmentation models can be deployed locally or via the cloud.
Additionally, the software includes the Hänscheid approach, which uses a single SPECT/CT image acquired around a chosen time after each therapy cycle to calculate the absorbed dose, and the prior-information approach, which uses time-activity curve information from multiple SPECT/CT scans after the first cycle to calculate the dose for the remaining cycles. The prior-information method uses only a single SPECT/CT at each of the remaining cycles.
The new AI segmentation models will be demonstrated at the upcoming RSNA 2021 annual meeting in Chicago.
